tobramycin inhalation / Generic mfg. - LARVOL DELTA

Inhaled tobramycin for eradication of Pseudomonas aeruginosa in bronchiectasis (ERS 2026) - P4 | "Background: The effect and optimal regimens for the eradication of Pseudomonas aeruginsa in bronchiectasis remain unclear. Among bronchiectasis patients with newly isolated P. aeruginosa, a 12-week course of TIS significantly increased P. aeruginosa eradication rates, regardless of whether it was combined with 2-week oral ciprofloxacin. (ERASE ClinicalTrials.gov number, NCT06093191)"

Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Antibiotic Therapy for Pseudomonas aeruginosa in Primary Ciliary Dyskinesia: Effectiveness and Key Influencing Factors (ERS 2026) - "AT, following cystic fibrosis protocols, included mainly inhaled tobramycin or colistin with oral ciprofloxacin or intravenous combination therapy guided by the antimicrobial susceptibility report. AT for PsA infections in pPCD demonstrates high efficacy and frequently achieves a durable response, even in recurrent or chronic cases. Ongoing data analysis, focusing on various influencing factors, will be presented at the conference."

Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

Cost savings associated with reduced inhaled therapy use in the CFTR modulator era: a real-world analysis in adults with cystic fibrosis (NACFC 2026) - "Reductions were also observed across multiple inhaled antibiotics, including nebulised colistimethate sodium (56 to 33; £42,473/year), nebulised tobramycin (35 to 21; £99,708/year), inhaled tobramycin (20 to 13; £75,180/year) and aztreonam (24 to 19; £98,169/year)...In contrast, prescribing of nebulised levofloxacin increased slightly (1 to 2), resulting in an additional annual cost of £13,089... In this real-world adult CF cohort, widespread uptake of CFTR modulators was associated with reduced prescribing of inhaled therapies and substantial reductions in associated drug costs. While these savings are substantial, they should be interpreted within the broader context of CFTR modulator costs. These findings demonstrate an evolving shift toward a lower treatment burden in selected individuals, with important implications for healthcare resource utilisation."

Clinical • HEOR • Real-world • Real-world evidence • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Experience of one year of elexacaftor/tezacaftor/ivacaftor in Egyptian people with CF (NACFC 2026) - "Background: Cystic Fibrosis (CF) has recently been acknowledged in Egypt and is currently being diagnosed widely. In general, Egyptian pwCF often present with more advanced disease, likely due to delayed diagnosis and limited resources. The introduction of ETI represents a significant advancement in CF care in this setting and has the potential to alter the disease trajectory. Despite limited availability of other CF therapies, including dornase alfa and inhaled tobramycin, ETI use was associated with significant improvements in nutritional parameters, including weight, height, and BMI."

Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

CF-HEAR: Rates of Hearing and Vestibular Abnormalities in People with Cystic Fibrosis Exposed to Ototoxic Therapies (NACFC 2026) - "Participants included PwCF ages 6 years and older currently or recently prescribed an oral macrolide (azithromycin) and/or an inhaled or intravenous (IV) aminoglycoside (amikacin or tobramycin)...In the three years prior to enrollment, 89% of PwCF were prescribed chronic azithromycin, 38% inhaled tobramycin, and 15% IV tobramycin... Utilizing a standardized screening approach for testing hearing and vestibular abnormalities in PwCF exposed to ototoxic medications, we identified a significantly higher proportion of PwCF with abnormalities than is reported in CF Foundation patient registry data. As the lifespan of PwCF continues to increase, this underscores the vital importance of a standardized, easily accessible approach to assessing this in PwCF to identify opportunities for intervention to improve quality of life."

Cystic Fibrosis • Genetic Disorders • Immunology • Otorhinolaryngology • Respiratory Diseases

Effect of Nebulization Mode and Device Design on Tobramycin Delivery Using a Standardized Wall Compressed Air Source (NACFC 2026) - "Background: Inhaled tobramycin solution (300 mg/5 mL) is a cornerstone therapy for chronic Pseudomonas aeruginosa infection in cystic fibrosis (CF)... Nebulizer device design strongly influenced tobramycin delivery when operated using a standardized wall compressed air source. Breath actuation nearly doubled respirable dose and decreased environmental loss compared to constant output delivery. These findings support breathactuated delivery as a key strategy to maximize drug delivery efficiency and minimize environmental loss in cystic fibrosis therapy."

Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Respiratory Diseases

Inhaled Tobramycin for Pseudomonas Eradication Postlung Transplantation. (PubMed, Prog Transplant) - No abstract available

Journal • Transplantation

Symptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials. (PubMed, Cell Rep Med) - "In TORNASOL, tobramycin produces clinically meaningful QoL-B-RSS improvements (exceeding the 8-point cutoff in high-symptom patients) and ameliorates bronchitic symptoms, with greater benefits in those with higher baseline symptom burden. These hypothesis-generating findings suggest that baseline symptom burden may identify differential responses to anti-inflammatory versus anti-infective therapies in bronchiectasis and support its potential as a simple, practical stratification tool to guide personalized treatment."

Journal • Retrospective data • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (clinicaltrials.gov) - P1/2 | N=71 | Completed | Sponsor: Respirion Pharmaceuticals Pty Ltd | Recruiting ➔ Completed

Trial completion • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Inhaled tobramycin for chronic pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis: an updated systematic review and meta-analysis. (PubMed, BMC Pulm Med) - No abstract available

Journal • Retrospective data • Review • Bronchiectasis • Genetic Disorders • Immunology • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Case of Effective Long-Term Tobramycin Inhalation in a Patient With Bronchiectasis and Refractory Pseudomonas aeruginosa Infection. (PubMed, Respirol Case Rep) - "Ceftazidime was effective; however, the patient could not be discharged because symptoms worsened immediately after its discontinuation. Furthermore, P. aeruginosa isolated from sputum 1 year after initiating nebulised tobramycin regained susceptibility to quinolones. This case suggests that nebulised tobramycin is a viable and effective option for long-term management of chronic P. aeruginosa infection complicating bronchiectasis."

Journal • Bronchiectasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases

ERASE: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis (clinicaltrials.gov) - P4 | N=371 | Completed | Sponsor: Jin-Fu Xu | Recruiting ➔ Completed

Trial completion • Bronchiectasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Bacterial Resistance Associated With Inhaled Tobramycin for Prevention of Ventilator-Associated Tracheitis in Mechanically Ventilated Neonates and Children Without Cystic Fibrosis: An Observational Pilot Study. (PubMed, J Pediatr Pharmacol Ther) - No abstract available

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Pediatric tracheostomy-associated respiratory infections: an evolving paradigm. (PubMed, Curr Opin Pediatr) - "With recent advances in TRAIN pathobiology, diagnosis, treatment, and prevention of TRAINs is undergoing a paradigm shift. Future translational research will define the airway microbiome during TRAINs and during wellness and its impact on host inflammation. Antibiotic clinical trials are needed to optimize treatment and prevention of TRAINs."

Journal • Infectious Disease • Inflammation • Pediatrics • Pneumonia • Respiratory Diseases

A Silent Complication: Rare Case of Inhaled Tobramycin Associated Ototoxicity in Patient With Preserved Renal Function (ATS 2026) - No abstract available

Clinical • Bronchiectasis • Cough • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Application of inhaled tobramycin in the treatment of severe pneumonia patients with mechanical ventilation: a randomized, double-blind, parallel controlled, exploratory study (ChiCTR) - P4 | N=104 | Not yet recruiting | Sponsor: The Affiliated Hospital of Medical College Qingdao University, China; The Affiliated Hospital of Medical College Qingdao University, China

New P4 trial • Infectious Disease • Pneumonia • Respiratory Diseases

Molecular endotyping in people with bronchiectasis based on response to antibiotic treatment: iBEST study. (PubMed, ERJ Open Res) - "Using molecular methods, we analysed changes in the sputum microbiota in samples from 107 participants with bronchiectasis recruited to the iBEST-1 study, and defined community endotypes based on response to tobramycin inhalation powder (TIP) treatment...qPCR may be a useful, culture-independent microbiological efficacy end-point in clinical trials. Using qPCR, participants with bronchiectasis were stratified into endotpyes which predicted response to antimicrobial treatment, potentially allowing for a more personalised approach to therapy."

Journal • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Respirion Pharmaceuticals Pty Ltd | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Inhaled Tobramycin Dose and Systemic Absorption in Lung Transplant Recipients Without Cystic Fibrosis. (PubMed, Transpl Infect Dis) - "LTRs without CF commonly had systemic tobramycin exposure during inhaled therapy. The 300 mg dose was linked to higher serum concentrations, supporting reduced dosing and active serum concentration monitoring to enhance safety."

Journal • Acute Kidney Injury • Cystic Fibrosis • Genetic Disorders • Immunology • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Transplantation

The Effect of Inhaled Tobramycin Use in Neonatal and Pediatric Intensive Care Unit Populations (ASHP 2025) - No abstract available

Clinical • Critical care • Pediatrics

Evaluation of Inhaled Tobramycin Use in the Neonatal Intensive Care Unit (ASHP 2025) - No abstract available

Critical care

Inhaled Tobramycin Systemic Absorption in Lung Transplant Recipients without Cystic Fibrosis (ASHP 2025) - No abstract available

Clinical • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases • Transplantation

Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach. (PubMed, J Adv Res) - "This tobramycin spongy-like dry powder, identified as high lectin affinity and excellent respiratory variability tolerance, holds significant promise for the treatment of pulmonary infections."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Recurrent Lung Infections In A kidney Transplant Patient: A Diagnostic Clue Reveals CD19 Deficiency. (ACAAI 2025) - "Her immunosuppressive regimen included mycophenolate, tacrolimus, and prednisone, with recent addition of inhaled tobramycin. Discussion In kidney transplant recipients with recurrent infections, persistent CD19+ B cell deficiency—even in the presence of normal immunoglobulin levels—should prompt consideration of functional antibody defects. Early recognition by pre & post transplant Immunoglobulin levels and CD19 counts are key to optimizing outcomes in this vulnerable population."

Clinical • Immunology • Infectious Disease • Nephrology • Pneumococcal Infections • Pneumonia • Primary Immunodeficiency • Respiratory Diseases • Solid Organ Transplantation • Transplantation • CD4 • CD8

An Unusual Overlap: Coexisting Cystic Fibrosis and Common Variable Immunodeficiency-like Phenotype in an Adult Patient (ACAAI 2025) - "Despite being on an optimized CF regimen, including Trikafta, Pulmozyme, albuterol, olodaterol, and inhaled tobramycin, he experienced over 90 CF exacerbations. In patients with CF who continue to experience frequent exacerbations despite optimal management, further immunologic evaluation should be considered. Early identification and initiation of therapy may lead to improved outcomes"

Clinical • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Hepatology • Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency • Psychiatry • Pulmonary Disease • Respiratory Diseases • CD4